Cognition Therapeutics’ (CGTX) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $11.00 price objective on the stock.

Several other brokerages have also recently issued reports on CGTX. B. Riley restated a “neutral” rating and issued a $1.00 target price (down from $5.00) on shares of Cognition Therapeutics in a report on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Cognition Therapeutics in a research note on Monday, November 4th. Finally, Cantor Fitzgerald cut shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 30th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Cognition Therapeutics Trading Down 9.9 %

CGTX stock traded down $0.05 during mid-day trading on Friday, reaching $0.46. The company’s stock had a trading volume of 336,050 shares, compared to its average volume of 493,689. The stock has a market cap of $18.51 million, a PE ratio of -0.48 and a beta of 1.34. The company’s 50 day moving average is $0.50 and its two-hundred day moving average is $1.21. Cognition Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.95.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CGTX. CM Management LLC boosted its position in shares of Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after buying an additional 25,000 shares during the period. Levin Capital Strategies L.P. acquired a new position in Cognition Therapeutics during the 1st quarter worth about $55,000. Mercer Global Advisors Inc. ADV boosted its holdings in Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after acquiring an additional 24,050 shares during the period. Tocqueville Asset Management L.P. acquired a new position in Cognition Therapeutics in the 1st quarter valued at about $47,000. Finally, Sigma Planning Corp increased its stake in Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares during the period. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.